TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Catheterization~   1. Elevated pulmonary arterial pressure (PA mean \>25mmHg)~  2. Elevated pulmonary vascular resistance (\>240 dynes.cm.sec-5) or transpulmonary gradient (\>12 mmHg)~  3. Elevated LVEDP (\>15mmHg, but ≤23 mmHg)~2. Evidence of left ventricular diastolic dysfunction: LA\>4.0, LVH or diastolic dysfunction by mitral filling pattern~3. Echocardiogram: Normal or mildly reduced LV ejection fraction (greater than or equal to 40%)~4. Symptomatic chronic HF (WHO functional class II-IV)~5. Baseline walk distance 100 to 400 meters~6. Age 18 - 80 (increased from 70)~Maximal treatment of diastolic dysfunction as noted by the treating physicians with no change in medical therapy for one month prior to entry~Exclusion Criteria:~1. Use of endothelin receptor antagonist, prostacyclin or PDE-5 inhibitor within 4 weeks of enrollment~2. Exercise capacity limited by other illness (other lung disease, arthritis, mobility limitations)~3. Uncontrolled systemic hypertension~4. Uncontrolled atrial fibrillation~5. Severe valvular disease~6. Pregnant females- females of child bearing potential will need to use contraceptive agent barrier given the teratogenicity associated with ERA's~7. Uncontrolled OSA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged 15 to 49 years~* Attending ANC clinic for the first time in this pregnancy~* Assigned routine ANC at a HCC health clinic~* Has experienced quickening (feeling the movements of the fetus)~* Gestation of 16 weeks to 32 weeks (as assessed by the last menstrual period \[LMP\] or by palpation if LMP is not available)~* Willing to adhere to all requirements of study~* Willing to provide informed written consent~* Planning to stay in Honiara for antenatal care and delivery~Exclusion Criteria:~* Used chloroquine prophylaxis in the current pregnancy before this ANC visit~* A history of allergic reaction to sulfa drugs (SP or cotrimoxazole~* Haemoglobin of \< 7 g/dl~* Using folic acid in a dose of 5 mg daily (a dose of 1 mg daily or less is acceptable)~* Not willing to adhere to study requirements~* Women who are severely ill

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Chloroquine prophylaxis (Type: ACTIVE_COMPARATOR): 300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
- IPTp with Sulphadoxine-pyrimethamine (Type: ACTIVE_COMPARATOR): 3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria include (but not limited to):~* Have a diagnosis of Rheumatoid Arthritis (according to the revised 1987 criteria of the American Rheumatism Association).~* Treatment with infliximab and methotrexate for \>= 9 months, (with stable doses of methotrexate over last 16 weeks of 7.5 mg/week to 25 mg/week) and (anti-TNFα therapy with infliximab 2 - 4 mg/kg every 4 weeks, 2 - 5 mg/kg every 5 weeks, 3 - 6 mg/kg every 6 weeks, 3 - 7mg/kg every 7 weeks, or 4 - 8 mg/kg every 8 weeks).~* Disease Activity Score 28 (DAS28) ≥ 3.2 based on Erythrocyte Sedimentation Rate (ESR) at Week -8 and Week 0.~* Swollen joint count (SJC) ≥ 4 and tender joint count (TJC) ≥ 4 at Week - 8 and at Week 0.~* Prior response confirmed by physician.~Major Exclusion Criteria include (but not limited to):~* Have a history of latent or active granulomatous infection, including histoplasmosis, or Have a history of latent or active granulomatous infection, including histoplasmosis, or coccidioidomycosis, prior to the first screening visit or during the Screening Period.~* Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.~* Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis.~* Have previously received more than 1 of the currently approved subcutaneous (SC) administered anti-TNFα agents, etanercept, certolizumab pegol, golimumab, or adalimumab.~* Are pregnant, nursing, or planning a pregnancy or fathering a child within 6 months after receiving the last administration of the study agent.~* Weight less than 35 kg or greater than 110 kg (less than 77 pounds or greater than 242 pounds).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab 2 mg/kg IV (Type: EXPERIMENTAL): Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Computed Tomography-derived Fractional Flow Reserve STAT Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency department chest pain suspicious for ACS based on history and physical examination.~* At least one biomarker (troponin) and electrocardiogram with no evidence of definite ACS.~* A completed CCTA demonstrating \>50% but \<90% stenosis of at least one coronary artery branch.~* CCTA test images with sufficient diagnostic quality for CTFFR analysis.~* Ability and willingness to provide informed consent.~Exclusion Criteria:~* Left main coronary stenosis of 50% or greater.~* CCTA lesions demonstrating stenosis \>90% (subtotal), or complex, high-risk plaque characteristics resulting in an a priori recommendation for triage to CATH by the CCTA interpreting physician.~* Attending physician a priori decision for CATH.~* Previous coronary stent, coronary bypass or prior known myocardial infarction.~* Clinical instability, such as hypotension, signs of shock, and/or accelerating chest pain requiring admission.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOC Group Management (Type: ACTIVE_COMPARATOR): Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
- CTFFR-Guided Group Management (Type: EXPERIMENTAL): Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women greater than 18 years of age~* Undergoing primary elective valve surgery at Brigham and Women's Hospital~* Consented for Transesophogeal Echocardiography (TEE) as part of routine intra-operative care and monitoring~Exclusion Criteria:~* Patients not consented for TEE as part of routine intra-operative care~* Any absolute contraindication to TEE~* Ionized calcium level \< 0.80 mmol/L near separation from CPB~* Myocardial infarction (MI) or acute coronary syndromes \< 3 months prior to surgery due to the presence of pre-operative diastolic dysfunction in infarcted or ischemic myocardium~* Ejection fraction (EF) \< 35%~* Atrial fibrillation / flutter the absence of an A wave on mitral inflow Doppler~* Heart rate (HR) \> 100 during 2 data point collections due to E / A wave superimposition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcium Chloride (Type: ACTIVE_COMPARATOR): Calcium chloride, 10mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed (within last 3 months)progressive Stage IV NSCLC~* estimated life span of 3 months~* phase angle of at least 5 as measured by bioimpedance~Exclusion Criteria:~* currently taking a lipid lowering medications~* has an imminently life threatening condition~* has pre-existing liver disease~* known allergy to soybeans~* uncontrolled diabetes or uncontrolled disturbance of lipid metabolism~* pregnant or lactating~* has a pacemaker or other implantable electronic medical device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kanglaite injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with S. aureus or E. coli bacteriostatic bacteremia defined by at least one positive blood culture bottle~* Patient requiring a blood test as part of his bacteremia~* not subject to a judicial protection measure~* Signature of the non-opposition of consent (for minor patients signed by one of the parents or the representative of the parental authority)~* Affiliation to social security~Exclusion Criteria:~* Immunocompromised patient defined by:~  * current immunosuppressive therapies: corticosteroids, chemotherapy, biotherapy~ * solid organ transplant patient or hematopoietic stem cell transplant~ * chemotherapy-induced neutropenia~ * Congenital immune deficiency~* bacteremia related to a peripheral or central catheter~* Urinary obstruction not lifted within the first 24 hours of management~* Intra-abdominal infection collected undrained in the first 24 hours of management~* primary infectious focus represented by mechanically ventilated pneumonia~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Patients presenting E. coli and S. aureus bacteremia (Type: None): Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Stable plaque psoriasis, duration \> 1 year.~2. Patients with Chinese medicine blood stasis syndrome. (2)18 to 65 years old, male or female patient.~3. Mild psoriasis:3\<PASI≤10, and BSA≤10%.~4. Informed consent.~Exclusion Criteria:~1. Guttate psoriasis, inverse psoriasis or exclusively involves the face;~2. Acute progression of psoriasis, and erythroderma tendency.Not blood stasis syndrome.Not stable psoriasis.~3. Pregnant, lactating, or which one plan to become pregnant in a year;~4. SAS（Self-rating Anxiety Scale）\> 50 or SDS（Self-rating Depression Scale）\> 53, or with other psychiatric disorders;~5. With history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. Either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder.~6. Allergic to any medicine or ingredients used in this study.~7. Participating other clinical trials or participated within 1 month.~8. Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks.~9. Patients need systemic treatment prescribed by doctors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PSORI-CM01（YXBCM01）granule (Type: EXPERIMENTAL): PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
- PSORI-CM01（YXBCM01）granule low dose group (Type: EXPERIMENTAL): PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
- placebo (Type: PLACEBO_COMPARATOR): Placebo granule 1.1g os once a day for 12weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation Length in Cancer Associated Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving LMWH for treatment of CAT for five months~* Locally advanced or metastatic cancer~* Able to self-administer LMWH, or have LMWH administered by a carer~* Able to give informed consent~* Age ≥16 years~Exclusion Criteria:~* Receiving drug other than LMWH for CAT~* Contraindication to anticoagulation~* Fitted with a prosthetic heart valve~* Pregnant and/or lactating females

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Continue treatment (Type: EXPERIMENTAL): Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
- B: Discontinue treatment (Type: NO_INTERVENTION): Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Prior enrollment in Study B2801001 and dosing with TT-034~* An informed consent form for this study signed and dated by the subject or a legally acceptable representative~Exclusion Criteria:~* There are no specific exclusion criteria for this follow-up study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosed subjects (Type: None): There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of TENS on Patients With Palmar Hyperhidrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Age range from 18 to 30 years old.~  * Patients will be from both sexes.~ * Body mass index from 18.5 to 24.9~ * Subject suffer from primary palmar hyperhidrosis.~ * No clinical treatment for palmar hyperhidrosis within the past month.~Exclusion Criteria:~* • Patients outside the target range.~  * Patients who were pregnant or lactating.~ * Patients who had metal implants such as a pacemaker.~ * Patients who had history of ischemic heart disease or arrhythmias.~ * Patients who had any other diseases that could be the cause ofsecondary hyperhidrosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- TENS arm (Type: EXPERIMENTAL): This arm who was experimental group who received transcutaneous electrical nerve stimulation and breathing exercises
- Breathing arm (Type: SHAM_COMPARATOR): This arm was sham and not received official treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All subjects: Able and willing to undergo the test procedures, sign informed consent, and follow instructions.~* Age ≥ 22~Subjects with Normal Eyes:~* Corrected visual acuity ≥ 20/40 in each eye~Subjects with Pathology:~* Subjects with vascular retinal conditions in at least one eye~* Subjects included should have a range of retinal vascular pathologies likely to appear in OCTA imaging, affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included.~Exclusion Criteria:~* All Subjects:~* Subjects unable to read or write~* Subjects with ocular media not sufficiently clear to obtain acceptable study- related imaging~* Subjects who cannot tolerate the imaging procedures~* Subjects with contraindication to pupillary dilation in the study eye~* Subjects with Normal Eyes:~* Subjects with uncontrolled systemic conditions, or ocular disease, as determined by the Investigator, during the eye exam and CFP~* History of ocular surgical intervention (except for refractive or cataract surgery) in either eye

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Subjects with Normal Eyes (Type: None): Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
- Subjects with Retinal Vascular Pathology (Type: None): Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues